Evidence map›Paper›PMID 35839803›Full record

ArticleThe Lancet. Global health2022

Cancer care cost-effectiveness in low-income and middle-income countries: time to shift the burden of proof.

Matthew S Painschab

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Matthew S PainschabUNC Project Malawi, Private Bag A-104, Lilongwe, Malawi; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: painschabm@med.unc.edu.

Funding

The road to recovery: An assessment of patient-reported quality of life among cancer survivors in Malawi.U54CA254564 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HOSSEINIPOUR, MINA CHRISTINE · 2020 to 2024
$6.1M
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in MalawiK01TW011470 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PAINSCHAB, MATTHEW SCOTT · 2019 to 2023
$720k
FIC NIH HHS K01 TW011470FIC NIH HHS L30 TW011802NCI NIH HHS L30 CA233709
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Developing CountriesNeoplasmsCost-Benefit AnalysisHumansIncomePoverty

Identifiers

PMID35839803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.